Amygdala Reactivity, Antidepressant Discontinuation, and Relapse
JAMA Psychiatry · 01.11.2024 · 81 (11) · 1081
DOI: 10.1001/jamapsychiatry.2024.2136 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA Psychiatry, erschienen am 01.11.2024. Verfasst von Tore Erdmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Applied Computational Psychiatry Lab, Mental Health Neuroscience Department, Division of Psychiatry and Max Planck Centre for Computational Psychiatr…. Hauptthemen laut MEDLINE: Amygdala, Major Depressive Disorder, Antidepressive Agents, Recurrence. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Importance Antidepressant discontinuation substantially increases the risk of a depression relapse, but the neurobiological mechanisms through which this happens are not known. Amygdala reactivity to negative information is a marker of negative affective processes in depression that is reduced by antidepressant medication, but it is unknown whether amygdala reactivity is sensitive to antidepressant discontinuation or whether any change is related to the risk of relapse after antidepressant discontinuation.
Objective
To investigate whether amygdala reactivity to negative facial emotions changes with antidepressant discontinuation and is associated with subsequent relapse. Design, Setting, and Participants The Antidepressiva Absetzstudie (AIDA) study was a longitudinal, observational study in which adult patients with remitted major depressive disorder (MDD) and currently taking antidepressants underwent 2 task-based functional magnetic resonance imaging (fMRI) measurements of amygdala reactivity. Patients were randomized to discontinuing antidepressants either before or after the second fMRI measurement. Relapse was monitored over a 6-month follow-up period. Study recruitment took place from June 2015 to January 2018. Data were collected between July 1, 2015, and January 31, 2019, and statistical analyses were conducted between June 2021 and December 2023. The study took place in a university setting in Zurich, Switzerland, and Berlin, Germany. Of 123 recruited patients, 83 were included in analyses. Of 66 recruited healthy control individuals matched for age, sex, and education, 53 were included in analyses. Exposure Discontinuation of antidepressant medication. Outcomes Task-based fMRI measurement of amygdala reactivity and MDD relapse within 6 months after discontinuation.
Results
Among patients with MDD, the mean (SD) age was 35.42 (11.41) years, and 62 (75%) were women. Among control individuals, the mean (SD) age was 33.57 (10.70) years, and 37 (70%) were women. Amygdala reactivity of patients with remitted MDD and taking medication did not initially differ from that of control individuals ( t 125.136 = 0.33; P = .74). An increase in amygdala reactivity after antidepressant discontinuation was associated with depression relapse (3-way interaction between group [12W (waited) vs 1W2 (discontinued)], time point [MA1 (first scan) vs MA2 (second scan)], and relapse: β, 18.9; 95% CI, 0.8-37.1; P = .04). Amygdala reactivity change was associated with shorter times to relapse (hazard ratio, 1.05; 95% CI, 1.01-1.09; P = .01) and predictive of relapse (leave-one-out cross-validation balanced accuracy, 67%; 95% posterior predictive interval, 53-80; P = .02). Conclusions and Relevance An increase in amygdala reactivity was associated with risk of relapse after antidepressant discontinuation and may represent a functional neuroimaging marker that could inform clinical decisions around antidepressant discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Applied Computational Psychiatry Lab, Mental Health Neuroscience Department, Division of Psychiatry and Max Planck Centre for Computational Psychiatry and Ageing Research, Queen Square Institute of Neurology, University…
- Princeton Neuroscience Institute & Psychology Department, Princeton University, Princeton, New Jersey.
- Translational Neuromodeling Unit, University of Zurich and Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland.
- Max Planck Institute for Metabolism Research, Cologne, Germany.
- Department of Adult Psychiatry and Psychotherapy, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.
- Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Förderung
- Wellcome Trust
Zitieren
APA
Erdmann, T., Berwian, I. M., Stephan, K. E., Seifritz, E., Walter, H., & Huys, Q. J. M. (2024). Amygdala Reactivity, Antidepressant Discontinuation, and Relapse. JAMA Psychiatry, 81(11), 1081. https://doi.org/10.1001/jamapsychiatry.2024.2136
Vancouver
Erdmann T, Berwian IM, Stephan KE, Seifritz E, Walter H, Huys QJM. Amygdala Reactivity, Antidepressant Discontinuation, and Relapse. JAMA Psychiatry. 2024;81(11):1081. doi:10.1001/jamapsychiatry.2024.2136
BibTeX
@article{Erdmann2024,
author = {Erdmann, Tore and Berwian, Isabel M and Stephan, Klaas Enno and Seifritz, Erich and Walter, Henrik and Huys, Quentin J M},
title = {Amygdala Reactivity, Antidepressant Discontinuation, and Relapse},
journal = {JAMA Psychiatry},
year = {2024},
volume = {81},
number = {11},
pages = {1081},
doi = {10.1001/jamapsychiatry.2024.2136}
}
EUVIMED